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Adipose tissue macrophage (ATM)-driven inflamma-
tion plays a key role in insulin resistance; however,
factors activating ATMs are poorly understood. Us-
ing a proteomics approach, we show that markers
of classical activation are absent on ATMs from
obese humans but are readily detectable on airway
macrophages of patients with cystic fibrosis, a dis-
ease associated with chronic bacterial infection.
Moreover, treating macrophages with glucose, insu-
lin, and palmitate—conditions characteristic of the
metabolic syndrome—produces a ‘‘metabolically
activated’’ phenotype distinct from classical activa-
tion. Markers of metabolic activation are expressed
by proinflammatory ATMs in obese humans/mice
and are positively correlated with adiposity. Meta-
bolic activation is driven by independent proinflam-
matory and anti-inflammatory pathways, which regu-
late balance between cytokine production and lipid
metabolism. We identify PPARg and p62/SQSTM1
as two key proteins that promote lipid metabolism
and limit inflammation in metabolically activated
macrophages. Collectively, our data provide impor-
tant mechanistic insights into pathways that drive
the metabolic-disease-specific phenotype of macro-
phages.
INTRODUCTION
Macrophages accumulate in adipose tissue of obese mice
and humans (Weisberg et al., 2003; Xu et al., 2003) and are614 Cell Metabolism 20, 614–625, October 7, 2014 ª2014 Elsevier Inkey contributors to inflammation and obesity-induced insulin
resistance (Chawla et al., 2011; Lumeng and Saltiel, 2011;
Olefsky and Glass, 2010; Wellen and Hotamisligil, 2005). The
evidence implicating adipose tissue macrophage (ATM) inflam-
mation in potentiating insulin resistance is substantial. Indeed,
ablation of proinflammatory (CD11c+) ATMs using a diphtheria
toxin system led to rapid improvements in insulin sensitivity
and glucose tolerance, associated with marked decreases in
local and systemic inflammation in obese mice (Patsouris
et al., 2008). Moreover, targeting pathways that mediate inflam-
mation in the macrophage revealed significant roles for TLR4,
JNK, and IKKb in potentiating ATM inflammation and insulin
resistance in mice (Arkan et al., 2005; Han et al., 2013; Saberi
et al., 2009). Anti-inflammatory effects may also help explain
the insulin-sensitizing action of thiazolidinediones (TZDs). In-
deed, myeloid-specific deletion of PPARg, the molecular target
of TZDs, exacerbated macrophage inflammation and insulin
resistance (Odegaard et al., 2007).
Macrophages are heterogeneous, and based on patterns of
gene expression and function, they have been classified as clas-
sically (M1) or alternatively (M2) activated (Gordon and Taylor,
2005). The M1 phenotype is promoted by Th1 mediators such
as LPS and IFNg and is characterized by the overproduction of
proinflammatory cytokines. In contrast, Th2 mediators (e.g.,
IL-4) drive the M2 phenotype, which activates expression of
immunosuppressive factors and peroxisome proliferator-acti-
vated receptor gamma (PPARg) that promote tissue remodeling
and helps resolve inflammation (Odegaard et al., 2007). It has
been proposed that during weight gain macrophages undergo
a ‘‘phenotypic switch’’ from an anti-inflammatory M2 phenotype
to a proinflammatory M1 state, a conversion that has been linked
to the emergence of systemic insulin resistance (Lumeng et al.,
2007).
Although it is clear that ATM activation is involved in regulating
insulin sensitivity, the mechanisms that underlie transition to thec.
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of cell surface markers are poorly understood. For example,
CD11c, the most commonly used marker of proinflammatory
ATMs in mice and humans, is suppressed by the classical
activation paradigm of LPS stimulation (Becker et al., 2012).
More recently, Ferrante and colleagues provided evidence that
ATMs in obese mice exhibit increased lipid metabolism and
further suggested that increases in ATM number, rather than
ATM activation, may be responsible for the low-grade inflamma-
tion observed in obesity (Xu et al., 2013). In addition, several
studies have described a ‘‘mixed’’ M1/M2 phenotype for ATMs
in obese mice and humans, suggesting that ATMs adopt more
complex states in vivo (Sica and Mantovani, 2012; Zeyda et al.,
2007). However, the etiologies of such mixed M1/M2 pheno-
types are incompletely understood.
Here we combine proteomic, gene expression, and flow cyto-
metric analyses of human and murine macrophages; studies of
cells from obese, nonobese, and cystic fibrosis (CF) patients;
and murine knockout studies to characterize proinflammatory
ATMs and to identify the molecular mechanisms that produce
them. Our findings demonstrate that treating macrophages
with mixtures of glucose, insulin, and palmitate (i.e., ‘‘metabolic
activation’’) produces a complex macrophage phenotype that is
mechanistically distinct from classical activation, suggesting
that metabolic-disease-specific pathways drive macrophage
inflammation via mechanisms that are different from those oper-
ative during infection.
RESULTS
Plasma Membrane Proteomics Identifies Markers of
M1 Macrophages
The lack of specific markers for human macrophage subsets is a
major hurdle to understanding ATM inflammation in obese and
diabetic patients (Geissmann et al., 2010). We therefore used a
plasma membrane (PM) proteomics approach to define protein
expression patterns diagnostic of proinflammatory human mac-
rophages. Initial studies focused on a widely used in vitro system
that included classically activated (M1, proinflammatory), alter-
natively activated (M2, anti-inflammatory), and unstimulated
(M0) macrophages generated from human peripheral blood
monocytes (Mn) in the presence of M-CSF (MM0, MM1, and
MM2) or GM-CSF (GM0, GM1, and GM2) (Figure 1A). Classical
and alternative activation were confirmed by measuring expres-
sion of genes associated with the M1 and M2 phenotypes (Fig-
ure S1 available online).
PM-associated proteins were biotinylated, affinity-isolated,
and analyzed by liquid chromatography-electrospray ioniza-
tion-tandem mass spectrometry. This approach identified 349
proteins with high confidence (Table S1). Gene ontology analysis
of those proteins validated our analytical strategy by revealing
strong enrichments in functional annotations consistent with
the PM compartment of macrophages (Figure S1).
Protein levels were quantified by spectral counting (Liu et al.,
2004), a measure of relative protein abundance, which were
closely correlated with flow cytometry data (Figure S1). Markers
of classically activated macrophages were selected by identi-
fying proteins consistently upregulated (or downregulated) by
both the t test and G test (Becker et al., 2010) in M1 cells relativeCellto M2 and M0 cells. We identified 52 significantly regulated PM
proteins in M1 macrophages differentiated by M-CSF or GM-
CSF treatment (Figure 1B; Table S1). We further required that
such markers were reproduced in macrophages differentiated
in the presence of M-CSF and GM-CSF, as we thought this
would increase their utility as markers in diverse environments
in vivo. Based on these stringent criteria, we identified 13 mem-
brane proteins as putative cell surface markers of M1 macro-
phages (Figures 1B and 1C; Table S1).
We previously used a similar PM proteomics approach to
define cell surface markers of M1 macrophages in mice (Becker
et al., 2012). Interestingly, only six of the M1markers identified in
human macrophages overlapped with those found in classically
activated bone-marrow-derivedmurinemacrophages (BMDMs).
To promote continuity between human and mouse studies, our
subsequent analyses focused on three such conserved markers
(CD274, CD38, and CD319). Flow cytometric measurements
validated the ability of CD274, CD38, and CD319 to reliably iden-
tify classically activated macrophages ex vivo using both human
and murine macrophages (Figures 1D and S1). Importantly, the
induction of CD38 and CD319 on the cell surface of M1 cells
was not attenuated by simultaneously exposing macrophages
to M1 and M2 stimuli (Figure 1E), suggesting that these markers
can report exposure to classical stimuli even in the context of a
‘‘mixed’’ macrophage phenotype, which is likely to be present
in more complex conditions in vivo (Mosser and Edwards, 2008).
To validate the ability of these markers to identify macro-
phages inflamed by bacterial stimuli in vivo, we tested the
expression of CD38, CD319, and CD274 on airway macro-
phages from infected patients with CF, a disease characterized
by heightened inflammatory responses in the airways due to
chronic respiratory tract infection with pathogenic bacteria like
Pseudomonas aeruginosa (Rowe et al., 2005). Flow cytometric
analysis detected strong expression levels for all three markers
in all CF patients examined (Figures 1F and S2). Thus, our prote-
omics approach successfully identified macrophage markers
expressed in an in vivo inflammatory condition caused by
chronic bacterial infection.
ATMs from Obese Humans and Mice Do Not Express
M1 Markers
During obesity, macrophages have been proposed to undergo a
‘‘phenotypic switch’’ from an anti-inflammatoryM2 phenotype to
a proinflammatory M1 state (Lumeng et al., 2007). To determine
if the M1markers discovered by proteomics and validated in pa-
tients with CF could identify proinflammatory ATMs, we studied
macrophages from omental and subcutaneous adipose tissue
obtained from obese (BMI > 30 kg/m2) subjects undergoing
bariatric surgery. For comparative purposes, we also investi-
gated ATMs in subcutaneous adipose tissue obtained from non-
obese (BMI < 30 kg/m2) subjects undergoing abdominoplasty.
Although proinflammatory cytokine expression was elevated in
both omental and subcutaneous adipose tissue from obese sub-
jects (Figure 2A), cell surface markers for M1 activation (CD38,
CD274, and CD319) were either not present or only very weakly
expressed by ATMs in either of the adipose tissue depots exam-
ined (Figures 2B, 2C, and S3).
We also tested the ability of M1 markers to identify proinflam-
matory ATMs in mice. To this end, we used a mouse model forMetabolism 20, 614–625, October 7, 2014 ª2014 Elsevier Inc. 615
Figure 1. PM Proteomics Identifies Markers of M1 Macrophages
(A) Conditions for differentiating and activating human monocyte-derived macrophages.
(B) Proteins consistently upregulated (or downregulated) in M1 relative to M0 and M2 macrophages were identified using a combination of the G test and
t test.
(C) The consensus markers of M1 macrophages; heatmap depicts regulation of protein expression across all cells types (blue = downregulated; yellow = up-
regulated).
(D) Validation of M1 markers by flow cytometry.
(E) Cell surface levels of CD319 and CD38 in macrophages exposed to M1 or M1/M2 (LPS, IFNg, and IL4); results are signal-to-noise ratio in mean fluorescence
intensity (MFI).
(F) Cell surface CD319, CD274, and CD38 levels in airway macrophages (defined as CD14+CD15) of a CF patient. Where applicable, results are means and
SEMs. *, denotes p < 0.05, t test relative to MM0; n = 6. See also Figures S1 and S2 and Table S1.
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C57BL/6 mice were placed on low-fat or high-fat diets for
16 weeks. Analysis of ATMs from lean and obese mice recapitu-
lated the findings obtained in human subjects. Thus, ATMs from
obesemicewere inflamed relative to their lean counterparts (Fig-
ure 2D) but did not overexpress CD319, CD274, or CD40 (Fig-
ure 2E), a previously characterized M1 marker in mice (Becker
et. al., 2012). Importantly, treating ATMs (purified from obese
mice) with LPS/IFNg in vitro induced expression of CD319,
CD274, and CD40, suggesting that ATMs are capable of
adopting an M1 phenotype given the appropriate environment
(Figure 2F). Collectively, these findings suggest that distinct
surface markers report macrophage inflammation in a setting
of bacterial infection and metabolic dysfunction.
‘‘Metabolically’’ and Classically Activated Macrophages
Express Distinct Cell Surface Proteins
The lack of M1 cell surface marker expression by proinflamma-
tory ATMs in obese humans and mice suggested that distinct616 Cell Metabolism 20, 614–625, October 7, 2014 ª2014 Elsevier Inpathways might promote macrophage inflammation in the
context of obesity, a hypothesis that has been proposed by Ho-
tamisligil and colleagues (Calay and Hotamisligil, 2013; Hotami-
sligil and Erbay, 2008). In the context of metabolic disease,
macrophage inflammation may be regulated by molecules
such as glucose, insulin, and palmitate, which are elevated in pa-
tients with metabolic disease (Despre´s and Lemieux, 2006).
Thus, we hypothesized that exposure to high levels of glucose,
insulin, and palmitate (‘‘metabolic activation’’; MMe) may pro-
duce a unique proinflammatory macrophage phenotype.
Classical and metabolic activation (Figure 3A) both induced
proinflammatory cytokine expression (Figure 3B). However,
MMe macrophages failed to express cell surface markers diag-
nostic of classically activated macrophages including CD38,
CD319, and CD274 (Figure 3C), a finding that resembled our
findings for proinflammatory ATMs isolated from obese humans
and mice (Figures 2B and 2C). To identify diagnostic cell surface
markers of metabolic activation, we performed membrane
proteomics of MM0, MM1, and MMe macrophages. Proteomicsc.
Figure 2. ATMs of Obese Humans and Mice
Are Not Classically Activated
(A–C) Omental (OM) and subcutaneous (SQ) adi-
pose tissue was collected from obese subjects
(BMI > 30 kg/m2) undergoing bariatric surgery
(n = 7). For comparative purposes, subcutaneous
adipose tissue was collected from nonobese
subjects (BMI < 30 kg/m2) undergoing abdomi-
noplasty (n = 7).
(A) Proinflammatory cytokine expression.
(B) Cell surface CD319 levels in ATMs (defined as
CD14+CD15CD206+CD1c) from a representa-
tive obese subject.
(C) Cell surface levels of CD38, CD274, and CD319
in ATMs from nonobese and obese subjects and
airway macrophages from CF patients; results are
signal-to-noise ratio in mean fluorescence in-
tensity (MFI).
(D–F) Male C57BL/6 mice were place on a low-fat
diet (LFD) or high-fat diet (HFD) for 16 weeks and
ATMs from epididymal fat were isolated.
(D) Proinflammatory cytokine expression.
(E) ATM cell surface CD319, CD274, and CD40
levels.
(F) ATM cell surface CD319, CD274, and CD40
levels in the presence and absence of M1 stimuli.
Where applicable, results are means and SEMs. *,
denotes p < 0.05, t test relative to nonobese or
LFD; n = 4–7. See also Figure S3.
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revealed remarkably distinct cell surface protein expression pat-
terns (<5% overlap) (Figure 3D; Table S2). For example, cell sur-
face proteins specifically overexpressed by MMe macrophages
included ABCA1, CD36, and PLIN2 (Figure 3E)—proteins in-
volved in lipid metabolism that have been associated with M2
macrophages. However, the M2 markers CD163, CD206,
TFRC, and TGFBI (Becker et al., 2012; Martinez et al., 2006)
were suppressed or not induced in MMe macrophages (Fig-
ure 3F), indicating that metabolic and alternative activation pro-
grams are distinct. In addition, proteomics analysis confirmed
that MMe macrophages did not express markers of classical
activation (Table S2).
Adipose Tissue Media Promotes ‘‘Metabolic Activation’’
of Macrophages
We considered the possibility that experimental exposure to
mixtures of glucose, insulin, and palmitate may inadequately
model in vivo ATM conditioning. To explore this, we treated hu-
man monocyte-derived macrophages with media conditionedCell Metabolism 20, 614–625by visceral adipose tissue from obese hu-
mans or mice and found that IL1b, TNFa,
ABCA1, and CD36 expression were all
induced (Figures 4A and 4B). In sharp
contrast, treatment with sputum from a
CF patient enhanced IL1b and TNFa
expression, and surface levels of CD274
and CD38, but failed to induce CD36
and PLIN2 in human macrophages (Fig-
ure 4A). Thus, treating naive macro-
phages with disease-specific biologicalfluids (adipose media versus CF sputum) reproduces the distinct
surface marker expression observed in airway macrophages
and ATMs in vivo (Figures 2 and 4).
Because adipocytes undergo lipolysis during culture and pref-
erentially release palmitate into the medium, we hypothesized
that palmitate was the major driver of metabolic activation. To
test this hypothesis, we compared MMe macrophages with
MM0 macrophages treated with glucose, insulin, or palmitate
in isolation. Treatment with palmitate was sufficient to drive
PLIN2 and IL1b expression, suggesting that it may be the main
driver of metabolic activation (Figure S4). We further confirmed
that palmitate levels at the lower limit in type 2 diabetic patients
(0.1 mM) (Reaven et al., 1988) could stimulate the MMe pheno-
type as well (Figure S4).
ATMs of Obese Humans and Mice Display Evidence of
‘‘Metabolic Activation’’
We investigated if markers of metabolic activation were present
on ATMs in vivo by quantifying ATM cell surface ABCA1 and
CD36 levels in omental and subcutaneous adipose tissue from, October 7, 2014 ª2014 Elsevier Inc. 617
Figure 3. Metabolically and Classically Activated Macrophages Are Distinct
(A) Conditions for metabolic (MMe) or classical (MM1) activation of human monocyte-derived macrophages.
(B) Proinflammatory cytokine expression.
(C) Flow cytometric analysis of cell surface CD38, CD319, and CD274 levels in MM0, MM1, and MMe macrophages. ISO, isotype control.
(D) PM proteomics analysis of MM0, MM1, and MMe macrophages.
(E and F) Quantification of cell surface proteins in MM0, MM1, and MMemacrophages by mass spectrometry (spectral count [SC]). Where applicable, results are
means and SEMs. *, denotes p < 0.05, t test relative to MM0; n = 6. See also Table S2.
Cell Metabolism
Metabolic-Disease-Specific Macrophage Inflammationobese subjects undergoing bariatric surgery. As before, sub-
cutaneous adipose tissue obtained from nonobese (BMI <
30 kg/m2) subjects undergoing abdominoplasty were used for
comparative purposes. Cell surface CD36 and ABCA1 levels
were elevated on ATMs from omental and subcutaneous adi-
pose tissue in obese relative to nonobese subjects and relative
to airway macrophages of CF patients (Figure 4C and S3). More-
over, linear regression analysis revealed strong relationships be-
tween BMI and ATMCD36 levels (R2 = 0.73, p = 0.0001, n = 14) or
ABCA1 levels (R2 = 0.40, p = 0.02, n = 14) in subcutaneous adi-
pose tissue (Figures 4D and 4E), suggesting that macrophage
metabolic activation correlates with adiposity. In sharp contrast,
such relationships were absent for markers of M1 macrophages
assessed in the same patients (CD38, CD319, and CD274; Fig-
ures 4D and 4E).
Analysis of ATMs from obese mice produced similar findings.
Indeed, we observed increases in the expression of proinflam-618 Cell Metabolism 20, 614–625, October 7, 2014 ª2014 Elsevier Inmatory cytokines (Tnfa and Il1b) and MMe markers (Plin2 and
Abca1) in ATMs isolated from obese mice (Figure 4F). Moreover,
ATMs isolated from obese mice overexpressed seven of nine
additional MMe markers identified in our proteomics analysis
of human MMe macrophages (Figure 4G). Collectively, these
findings are consistent with the notion that palmitate released
from adipocytes promotes macrophage metabolic activation
in vivo.
Proinflammatory Signaling Does Not Drive MMe Surface
Marker Expression
The fact that M1 and MMe macrophages differed markedly in
surface marker expression was surprising given that palmitate
is thought to mimic LPS action by binding to TLRs (Himes and
Smith, 2010; Shi et al., 2006). This finding led us to hypothesize
that different signaling pathways mediate the M1 and MMe phe-
notypes. To begin to test this hypothesis, we used bioinformaticsc.
Figure 4. ATMs Display Evidence of Metabolic Activation
(A) qRT-PCR analysis of human MM0macrophages treated with media conditioned by human omental fat (Ad-CM) or sputum collected from a CF patient. Inset:
Surface levels of CD38 and CD274.
(B) qRT-PCR analysis of murine macrophages (MM0) treated with media conditioned by epididymal adipose tissue collected from obese (Ad-CM-HFD) or lean
(Ad-CM-LFD) mice.
(C–E) Omental (OM) and subcutaneous (SUBQ) adipose tissue was collected from obese subjects (BMI > 30 kg/m2) undergoing bariatric surgery (n = 7). For
comparative purposes, subcutaneous adipose tissue was collected from nonobese subjects (BMI < 30 kg/m2) undergoing abdominoplasty (n = 7).
(C) Cell surface levels of CD36 and ABCA1 in ATMs; results are signal-to-noise ratio in mean fluorescence intensity (MFI).
(D) Relationships between BMI and cell surface CD36 or CD319 levels on ATMs (n = 14).
(E) Summary of linear regression analyses of cell surface protein levels on ATMs and BMI.
(F andG)Male C57BL/6micewere place on a LFD or HFD for 16weeks and ATMs from epididymal fat were purified and analyzed by qRT-PCR.Where applicable,
results are means and SEMs. *, denotes p < 0.05, t test relative to MM0 or nonobese or LFD; n = 4–7. See also Figure S3.
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proteins expressed by MM1 (but not MMe) macrophages.
LPS binding to TLR4 stimulates proinflammatory cytokine pro-
duction through the NFkB pathway and induces the type I inter-
feron response via IRF7 (Beutler, 2004). Consistent with this
idea, bioinformatics analysis suggested that cell surface proteins
selectively induced by MM1macrophages were associated with
the type I interferon response (p = 1030; Figure 5A). To confirm
the role of the type I interferon pathway in regulating M1 surface
markers, we performed two experiments that engaged the NFkB
pathwaywithout a type I interferon response. First, we compared
CD38, CD274, and CD319 expression in MM1 cells made from
wild-type and type I interferon pathway-deficient (Ifnar/)
mice (Mu¨ller et al., 1994). Ablation of Ifnar1 significantly lowered
cell surface CD38, CD274, and CD319 expression in M1 macro-
phages (Figure 5B). Second, we stimulated human macro-Cellphages with the TLR2 agonist Pam2CSK4. Pam2CSK4 induced
IL1b, TNFa, and IL6 expression to levels similar to MM1 macro-
phages (Figure 5C) but did not elicit the type I interferon response
(Toshchakov et al., 2002) (Figure 5D) or CD38, CD274, and
CD319 expression (Figure 5E). In addition, Pam2CSK4 treatment
did not elevate ABCA1, CD36, and PLIN2, suggesting that this
agonist does not stimulate metabolic activation (Figure 5F).
Given that the type I interferon pathway controls CD38,
CD274, and CD319 expression in M1 macrophages, and that
MMe cells express different cell surface proteins, we postulated
that that the type I interferon response would not be activated
in these cells. As expected, neither human nor murine MMe
macrophages exhibited IRF7 gene expression and IKKε phos-
phorylation (Figures 5G, 5H, and S5), two key drivers of the
type I interferon response (Honda et al., 2005). Proinflammatory
ATMs from obese mice also did not exhibit elevated IKKεMetabolism 20, 614–625, October 7, 2014 ª2014 Elsevier Inc. 619
Figure 5. Metabolic Activation Fails to Induce the Type I Interferon Response
(A) Heatmap depicts regulation of interferon-regulated proteins across human MM0, MM1, and MMe cells (blue = downregulated; yellow = upregulated).
(B) Comparison of M1 cell surface marker levels in MM1 macrophages made from wild-type (wt) and Ifnar/ mice.
(C–F) Human MM0 macrophages were classically activated or treated with Pam2CSK4, a selective agonist for TLR2.
(C) Proinflammatory cytokine expression.
(D) IRF7 expression.
(E) M1 cell surface markers were quantified by flow cytometry.
(F) qRT-PCR analysis of MMe markers.
(G and H) Human MM0 macrophages were classically or metabolically activated.
(G) Immunoblotting for total and phosphorylated (P-Ser172) IKKε.
(H) IRF7 expression.
(I–J) Male C57BL/6 mice were place on a LFD or HFD for 16 weeks and ATMs from epididymal fat were isolated.
(I) Immunoblotting for total and phosphorylated (P-Ser172) IKKε.
(J) Irf7 expression in purified ATMs. Where applicable, results are means and SEMs. *, denotes p < 0.05, t test relative to MM0; n = 4–6. Flow cytometry results
are expressed as signal-to-noise ratios in the mean fluorescence intensity (MFI). See also Figure S5.
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(Figures 5I and 5J).
Since MMe macrophages fail to engage the type I interferon
response, and activation of this pathway is a key feature of
TLR4 activation, we investigated whether surface markers
of MMe macrophages were dependent upon the presence of
TLRs. Ablation of Tlr2 or Tlr4, whichmediate the proinflammatory
effects of palmitate on macrophages (Himes and Smith, 2010;
Shi et al., 2006), attenuated Il1b expression but did not alter
Plin2 expression in MMe macrophages (Figure 6A). Collectively,
these studies demonstrate that, unlike MM1 macrophages, cell
surface markers of MMe macrophages are independent of the
type I interferon pathway and TLR activation.620 Cell Metabolism 20, 614–625, October 7, 2014 ª2014 Elsevier Inp62 and PPARg Promote MMe Surface Marker
Expression
What molecular mechanisms drive cell surface marker expres-
sion in MMe macrophages? We used two approaches to exploit
our proteomics data to identify signaling pathways controlling
cell surface marker expression in MMe macrophages.
First, we used bioinformatics analysis and found that surface
proteins selectively induced inMMemacrophages were involved
in lipid metabolism and regulated by PPARg (Figure 6B; p =
107). Consistent with the informatics data, chromatin immuno-
precipitation (ChIP) studies demonstrated increased binding of
PPARg to the promoters of PLIN2, ABCA1, and CD36 in human
and murine MMemacrophages (Figures 6C and S6), and PPARgc.
Figure 6. p62 and PPARg Promote MMe Marker Expression and Limit Inflammation
(A) Comparison of gene expression in MMe macrophages made from wt, Tlr2/, and Tlr4/ mice.
(B) Heatmap depicts regulation of PPARg-regulated proteins across human MM0, MM1, and MMe cells (blue, downregulated; yellow, upregulated).
(C) PPARg binding to its target gene promoters is increased in MMe relative to MM0 macrophages and correlated with abundance of the open chromatin mark
H3K4m3. Relative abundance of MM0 ChIP levels were arbitrarily set to 1.
(D) Protein levels of p62 in humanmacrophages in vitro (spectral counts [SC]) and in vivo (arbitrary units [AU]) inmurine ATMs isolated frommice fed a LFD or HFD.
(E) Comparison of gene expression in MMe and MM1 macrophages from wild-type and p62/ mice.
(F) Kinetics of p62 accumulation and LC3-I/-II levels in human MMe macrophages.
(G) p62 mRNA levels.
(H) p62 levels in MM0 and MMe macrophages made from wt, Tlr2/, and Tlr4/ mice.
(I) Kinetics of p62 accumulation and FFA uptake by human MMe macrophages.
(J) Varying numbers of human macrophages were metabolically activated, and palmitate uptake and p62 levels were determined. Where applicable, results are
means and SEMs. *, denotes p < 0.05, t test relative to MM0 or LFD; n = 3–6. See also Figures S6 and S7.
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(H3K4m3), an epigenetic mark for open chromatin (Figure 6C).
Furthermore, a PPARg antagonist (T0070907; 1 mM) reduced
ABCA1, PLIN2, and CD36 expression in MMe macrophages
(Figure S6).
Second,wesearched themembraneproteome forproteinswith
well-established roles in cell signaling that were selectively
induced in MMe macrophages. This analysis identified a strong
and selective induction of sequestome-1 (p62) (Figure 6D). More-
over, p62 was significantly elevated in ATMs from obese relative
to leanmice (Figure 6D). p62 is a scaffolding protein that regulates
avarietyofcell signalingcascades (Komatsuetal., 2007).Previous
studies suggest thatp62 regulatesadipocyte lipidmetabolismand
adiposity in mice (Mu¨ller et al., 2013; Rodriguez et al., 2006). To
determine if p62 regulates the MMe phenotype, we compared
macrophages from wild-type and p62-deficient (p62/) mice
and found Plin2, Abca1, and Cd36 expression was reduced in
p62/ cells (Figure 6E). Thus, p62 and PPARg regulate expres-
sion of CD36, ABCA1, and PLIN2 in MMe macrophages.Cellp62 and PPARg Limit Inflammation during ‘‘Metabolic
Activation’’
The induction of PPARg in proinflammatory MMe macrophages
seemed surprising given that saturated FFAs are poor PPARg
ligands (Wahli and Michalik, 2012) and that PPARg exerts anti-
inflammatory effects (Odegaard et al., 2007). We examined
the effect of PPARg on the inflammatory phenotype of MMe
macrophages by treating cells with the PPARg antagonist
T0070907. Consistent with an anti-inflammatory role of PPARg
(Odegaard et al., 2007), blocking PPARg with T0070907
increased expression of IL1b in MMe cells (Figure S6). The p62
induction identified in MMe macrophages (Figure 4D) also had
an anti-inflammatory effect, as p62/ macrophages markedly
overproduced Tnfa and Il1b in response to metabolic, but not
classical, activation (Figure 6E). These data indicate that p62
and PPARg attenuate proinflammatory cytokine production
during metabolic activation, which may in part explain why the
sterile inflammation associated with metabolic disease is often
of lower intensity than that induced by bacterial infection.Metabolism 20, 614–625, October 7, 2014 ª2014 Elsevier Inc. 621
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Inhibiting Autophagy
What mechanism induces p62 during metabolic activation?
Whereas p62 is normally degraded by the autophagolysosome,
it accumulates under conditions of failed autophagy (Komatsu
et al., 2007). Consistent with a blockade in autophagy in MMe
macrophages, p62 protein accumulated in a time-dependent
fashion (Figure 6F), and its accumulation could not be explained
by increased transcription (Figure 6G). Similarly, LC3-II protein,
another marker of failed autophagy (Shpilka et al., 2011), also
accumulated in MMemacrophages (Figure 6F). Moreover, treat-
ment with chloroquine (an inhibitor of autophagy) induced LC3-II
accumulation in MM0 macrophages but not in MMe macro-
phages (Figure S7).
How could metabolic activation inhibit autophagy? One
possibility is that this inhibition of autophagy is linked to the
proinflammatory state. Arguing against this possibility, MM1
macrophages did not accumulate p62 (Figure 6D), and inactiva-
tion of Tlr2 or Tlr4 inMMemacrophages abrogated proinflamma-
tory cytokine expression (Figure 6A) but had minimal effect on
p62 (Figure 6H).
In addition to binding to TLRs, palmitate is also internalized by
macrophages (Figure 6I), and the kinetics of palmitate internali-
zation and p62 accumulation in human macrophages was well
correlated (Figure 6I). Furthermore, increasing the amount of
palmitate ingested per cell by varying the ratio of palmitate to
the number of MMe macrophages in culture markedly increased
p62 accumulation (Figure 6J). Interestingly, ablation ofCd36 had
no effect on palmitate uptake by BMDMs in vitro (Figure S4), and
previous studies demonstrated normal palmitate uptake in
Cd36/ ATMs (Nicholls et al., 2011). Collectively, these findings
suggest that CD36-independent palmitate uptake has a greater
effect in suppressing autophagy and inducing p62 accumulation
than palmitate recognition by cell surface TLRs.
DISCUSSION
ATM inflammation plays a key role in obesity-associated insulin
resistance and type 2 diabetes (Chawla et al., 2011; Lumeng and
Saltiel, 2011; Olefsky and Glass, 2010; Wellen and Hotamisligil,
2005). A common observation reported in studying macro-
phages in obese mice and humans is that ATMs overexpress
proinflammatory cytokines via signaling pathways that are oper-
ative in M1macrophages, yet they cannot be identified when us-
ing cell surface markers of classical activation.
One possible explanation for these discordant findings is that
currently available surface markers for M1 macrophages, partic-
ularly in humans, may not be as specific as previously antici-
pated (Geissmann et al., 2010). To circumvent this problem,
we used a proteomics approach to define a set of cell surface
proteins that (i) report classical activation in human monocyte-
derived macrophages differentiated in the presence of M-CSF
or GM-CSF (two well-established paradigms for generating
macrophages in vivo), (ii) are maintained in macrophages
exposed tomixedM1/M2 stimuli, (iii) are conserved between hu-
man and mouse macrophages, and (iv) are validated in vivo in a
setting of chronic bacterial infection (CF patients).
Our findings show that markers identified by such stringent
approaches still fail to characterize proinflammatory ATMs622 Cell Metabolism 20, 614–625, October 7, 2014 ª2014 Elsevier Infrom obese subjects, both in omental and subcutaneous adi-
pose depots. Similar findings were obtained in our analyses of
ATMs isolated from obese mice in a DIO model. Collectively,
these data provide strong evidence that proinflammatory
ATMs do not adopt the classically activated M1 phenotype.
Our demonstration that cell surface markers of classical acti-
vation are primarily regulated by the type I interferon response
may have important implications for how proinflammatory ATM
phenotypes (and macrophage phenotypes in other diseases)
are conceptualized in vivo. Thus, dissociation of mechanisms
that control cell surface marker expression (how we detect mac-
rophages) from pathways that control cytokine production (how
we detect inflammation) enables these processes to be regu-
lated independently. In a setting of classical activation, both
pathways are coregulated by LPS (Beutler, 2004).
However, our data show that metabolic stimuli promote
inflammation without activating the type I interferon response,
a finding that is consistent with the inability of M1 markers to
identify MMe macrophages in vitro and proinflammatory ATMs
in vivo. Moreover, this concept may not be restricted to settings
of sterile inflammation, as bacterial products that are primarily
recognized by TLR2 also produce inflammation without acti-
vating the type I interferon response (Toshchakov et al., 2002),
an observation that we confirmed experimentally. Based on
these findings, it is likely that the repertoire of cell signaling path-
ways induced by a particular proinflammatory stimulus, and not
necessarily the extent of inflammation, determines the cell sur-
face markers that will ultimately be useful for interrogating that
cell type in vivo.
Thus, we propose that cell surface markers of macrophages
be used not to identify ‘‘cellular phenotypes,’’ but rather as
robust indicators of specific cell signaling pathways that are acti-
vated in a given microenvironment. Our approach for using dis-
ease-specific conditions to define diagnostic surface markers
and delineatemechanisms driving their expression can therefore
provide insights into the signaling pathways engaged and the
functional properties of the macrophages. In this respect, pro-
teins regulated by the type I interferon response, which identify
M1 macrophages, modulate host antiviral and antibacterial re-
sponses (Honda et al., 2005). On the other hand, metabolic
dysfunction and nutrient excess impose unique challenges for
ATMs. Insulin resistance in the adipocyte leads to a continuous
and excessive exposure of ATMs to FFA, particularly saturated
FFA such as palmitate, which our data suggest plays a key role
in triggering metabolic activation of macrophages. Thus, the in-
duction of proteins involved in lipid metabolism, which delineate
MMe macrophages, may enable these macrophages to appro-
priately buffer their environment from excessive lipids while
maintaining cell health. Importantly, saturated FFAs upregulate
proinflammatory cytokine expression in ATMs and fail to induce
theM2markers CD163, CD206, TFRC, and TGFBI (Becker et al.,
2012; Martinez et al., 2006), properties that clearly distinguish
these cells fromM2macrophages, which also induce lipid meta-
bolism through PPARg activation (Odegaard et al., 2007).
On a molecular level, the metabolically activated macrophage
phenotype is mediated by at least two independent mecha-
nisms: a pathway involving palmitate binding to cell surface
TLRs that drives proinflammatory cytokine production and a
pathway mediated by palmitate internalization that activatesc.
Figure 7. A Molecular Model for Metabolic
and Classical Activation of Macrophages
See text for details.
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inflammation (Figure 7). The balance between these two pro-
cesses determines the overall response of macrophages to
metabolic dysfunction (i.e., pro- or anti-inflammatory) and can
produce complex macrophage phenotypes spanning the spec-
trum between the ‘‘M1-like’’ and ‘‘M2-like’’ states. Indeed, our
analyses demonstrate strong correlations between cell surface
CD36 and ABCA1 levels on ATMs (markers often associated
with M2 macrophages) (Martinez et al., 2006) and metabolic
dysfunction in obese humans and mice. Concordant with our
findings, previous studies suggested the presence of mixed
macrophage phenotypes in obese human subjects and mice
(Sica and Mantovani, 2012; Zeyda et al., 2007).
Our model further predicts that excessive accumulation of
palmitate within the macrophage would further attenuate or
silence inflammation via p62 and PPARg activation and promote
a more ‘‘M2-like’’ ATM phenotype characterized by increased
lipid metabolism. Factors influencing the amount of FFAs in-
gested bymacrophages include adipose tissue mass, adipocyte
size, and extent of insulin resistance in the adipocyte, all of which
would increase with the degree of metabolic dysfunction in pa-
tients with type 2 diabetes. In mice, we would expect that dura-
tion of high-fat feeding regimens and themousemodel of obesity
used (Lepob/ob develop more severe metabolic dysfunction than
DIO) to greatly influence the ATM phenotype observed. Consis-
tent with these assumptions, previous studies demonstrated
that obesity-induced shifts in ATMs from a ‘‘M2-like’’ to a ‘‘M1-
like’’ phenotype (Lumeng et al., 2007) are reversed when mice
are fed a high-fat diet for extended periods of time (Shaul
et al., 2010). Similarly, recent work by Ferrante and colleagues
showed that ATMs of obese Lepob/ob mice (obese BW = 50–
70 g) are not inflamed, but rather are characterized by increased
lipid metabolism (Xu et al., 2013). In our analyses of more mildly
obese and insulin-resistant mice (DIO, obese BW = 30–35 g), we
observed upregulated cytokine expression in ATMs. However,
we also noted increases in genes involved in lipid metabolism,
suggesting that the anti-inflammatory pathway is operative but
not yet dominant.
In summary, our findings demonstrate that metabolic dysfunc-
tion leads to a macrophage phenotype that is mechanistically
distinct from classical activation, suggesting that disease-spe-
cific environments drive macrophage inflammation via different
mechanisms. Importantly, our data do not imply that treatingCell Metabolism 20, 614–625macrophages with adipose tissue or mix-
tures of glucose, insulin, and palmitate
can holistically model the ATM pheno-
type, since conditioning environments
in vivo are more complex and dynamic.
However, our data suggest that meta-
bolic activation is a suitable model for
conceptualizing ATM phenotype and
function, as it reconciles the seemingly
contradictory findings of elevated proin-flammatory cytokine expression in a cell expressing markers of
an ‘‘M2-like’’ phenotype. Future gene knockout studies that spe-
cifically attenuate signaling pathways driving metabolic activa-
tion will be required to more carefully delineate its contribution
to ATM inflammation and metabolic disease phenotypes in vivo.
EXPERIMENTAL PROCEDURES
Ethics
All human studies were approved by the Institutional ReviewBoards at the Uni-
versity of Washington (IRB#13293), Seattle Children’s Hospital (IRB#31279),
and Fred Hutchinson Cancer Research Center (IRB#6874). Animal studies
were approved by the Institutional Animal Care and Use Committee
(ACUP#72209) at the University of Chicago.
Differentiation and Activation of Human Monocyte-Derived
Macrophages
Peripheral blood monocytes were isolated from healthy donors and differenti-
ated to macrophages in the presence of M-CSF (125 ng/mL) or GM-CSF
(10 ng/mL), as previously described (Martinez et al., 2006). Treatments and ac-
tivations were performed for 24 hr as follows: M1, LPS (100 ng/mL) and IFNg
(20 ng/mL); M2, IL4 (20 ng/mL); MMe, glucose (30 mM) and insulin (10 nM) and
palmitate (0.4 mM); human adipose-tissue-conditioned media (1/10 dilution);
Pam2CSK4 (100 ng/mL); and chloroquine (100 mM). Resultant macrophage
populations were subjected to analysis by flow cytometry, qRT-PCR, immuno-
blotting, and PM proteomics.
PM Proteomics
Macrophage PM proteins were isolated using a membrane-impermeable
biotinylation reagent (N-hydroxysulfosuccinimide-SS-biotin; Pierce), as previ-
ously described (Becker et al., 2012). Mass spectrometric analyses and statis-
tical analyses of proteomics data were performed essentially as previously
described (Becker et al., 2010). Full details are provided in the Supplement
Information.
Bioinformatics Analysis
Functional analyses of the proteomics data were generated through the use of
IPA (Ingenuity Systems; http://www.ingenuity.com). Informatics data were
analyzed by the hypergeometric test with Benjamini-Hochberg correction.
Subject Recruitment (Elective Abdominal Surgeries)
Human adipose tissue was obtained from anonymous donors undergoing
abdominoplasty (n = 7) at Seattle Plastic Surgery or from study participants un-
dergoing laparoscopic intra-abdominal surgeries (n = 7) at the Puget Sound
Surgery Center in Edmonds, WA. Exclusion criteria included smoking; abuse
of alcohol or other drugs; pregnancy; history of cardiovascular, autoimmune,
or other chronic inflammatory disease; or current or recent use of antidiabetic,
anti-inflammatory, or steroid hormone drug., October 7, 2014 ª2014 Elsevier Inc. 623
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Human adipose tissue was collected by surgeons conducting abdominoplasty
(subcutaneous only) or intra-abdominal surgery (subcutaneous and omental)
and processedwithin 10min by study staff. Stromavascular cells were isolated
as previously described (Hagman et al., 2012). In some instances, a 100 mg
piece of freshly harvested adipose tissue was cultured in 1 mL media for
24 hr to obtain human adipose-tissue-conditioned media.
Subject Recruitment (CF)
Spontaneously expectorated sputum was collected in clinic or sent overnight
on ice from the patient’s home. Study participants were older than 18 yr of age
and had a confirmed diagnosis of CF. Exclusion criteria included significant
hemoptysis within 2 weeks of collection or a prior lung transplant.
Sputum Processing
To solubilize sputum, samples were mixed with an equal volume of 0.1% DTT
in PBS and placed on ice for 30 min with intermittent vortexing. Samples were
passaged through sterile cotton gauze and filtered through 70-mmnylon gauze
cell strainers. Cells were centrifuged at 3003 g for 10 min at 4C and washed
four times with 50ml RPMI to reduce debris. Cells were counted and assessed
for viability using trypan blue exclusion. If contaminated with saliva, salivary
components were aspirated from the sample prior to sputum processing.
Mouse Studies
Male C57BL/6 mice were obtained from Jackson laboratories. BMDMs were
isolated as previously described (Becker et al., 2012) and activated along
the MM1 andMMe pathways using identical conditions as for the humanmac-
rophages. For DIO studies, mice were fed a low-fat (Harlan Tekland; 2918) or
high-fat (Research Diets Inc.; D12451) diets for 16 weeks. Epididymal adipose
tissue was collected, washed, and subjected to collagenase digestion to
isolate stromavascular cells, and ATMs were purified using anti-CD11b
coupled magnetic beads (Miltyeni).
Flow Cytometry
Fluorochrome-labeled cells were analyzed according to the workflows pre-
sented in Figures S2 and S3. Analyses were conducted using a Canto-II or
LSRII flow cytometer (BD Biosciences), and data were analyzed using FlowJo
software v.9.4.11. Protein levels were quantified by mean fluorescence inten-
sity and normalized to isotype to facilitate comparison between patients.
Antibodies
Antibodies for flow cytometric measurements of ABCA1, CD1c, CD11c, CD14,
CD15, CD16, CD36, CD38, CD45, CD274, and CD319 were purchased from
BD Biosciences (San Jose), Beckman Coulter (Danvers), Novus Biologicals
(Littleton) BioLegend (San Diego), eBioscience (San Diego), or Miltyeni
(Auburn).
ChIP
ChIP experiments were performed as previously described (Mutskov et al.,
2002) using specific primers (Table S3) designed based on previously pub-
lished PPARg ChIP-seq data (Mikkelsen et al., 2010) and the RXR-binding
sites from the ENCODE project. Full details are provided in the Supplement
Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, three tables, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.cmet.2014.08.010.
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